← FDA DRUG APPROVALS

FDA ANDA · ANDA206699

PARICALCITOL

Sponsor: AMNEAL PHARMS CO

APPLICATION
ANDA206699
TYPE
ANDA
ORIGINAL APPROVAL
2017-03-09
LATEST ACTION
2019-05-21
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

PARICALCITOLPrescription
PARICALCITOL 0.005MG/ML (0.005MG/ML) · SOLUTION · INTRAVENOUS
PARICALCITOLPrescription
PARICALCITOL 0.01MG/2ML (0.005MG/ML) · SOLUTION · INTRAVENOUS
PARICALCITOLPrescription
PARICALCITOL 0.002MG/ML (0.002MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2019-05-21Labeling · Supplement 1 · standardAP
2017-03-09UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →